Ariana Pelosci

A genomic-adjusted radiation dose model can aid in predicting radiotherapy benefit vs physical dose of radiotherapy pan-cancer.

The prospective observational Precision1 cohort study will integrate imaging technology with actionable whole genome sequencing in patients with primary and secondary liver cancer.

The World Health Organization has published new recommendations to aid in the global prevention of cervical cancer through more accessible screenings and treatments.

Patients with recurrent pancreatic cancer could potentially benefit from stereotactic body radiotherapy plus pembrolizumab and trametinib post-surgery.

At a population level, those who were selected for surgery had a greater risk of dying from cancer related causes than dying from non-cancer causes.

Investigators advise against the use metformin in addition to chemoradiotherapy for patients with locally advanced non–small cell lung cancer due to progression-free survival and overall survival was not substantial.

Toripalimab in combination with chemotherapy yielded an improvement in progression-free survival compared with placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.

Although most patients with cancer who received both doses of the COVID-19 vaccine developed a good immune response within the following 3 weeks, investigators emphasized the importance of developing alternative strategies for patients who are at a high risk of not responding.

Patients undergoing colon cancer treatment can either use their general practitioner or surgeon to lead their survivorship and improving quality of life.

Use of economic coping mechanisms were associated with scoring 26 or lower on the COST analysis, or Comprehensive Score for Financial Toxicity, in patients being treated for gynecologic cancers.

A systemic review and network meta-analysis investigated 3 trials and determined that acalabrutinib/obinutuzumab up front prolongs progression-free survival for patients with chronic lymphocytic leukemia vs other regimens.

Pediatric patients with high-risk molecular subgroup group 3 medulloblastoma experienced an improvement in 5-year event-free survival after receiving therapy intensification with carboplatin.

The phase 2 KEYNOTE-158 trial has demonstrated promising responses in patients with microsatellite instability–high/ mismatch repair deficient advanced endometrial carcinoma, and led to the FDA accepting a review of a new supplemental biologics license application for the drug.

A study published in Lancet Oncology indicated that children with low-risk acute lymphoblastic leukemia may be able to safely omit pulse therapy after 1-year of treatment.

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone helped patients to achieve a significantly improved progression-free survival over the standard of care for previously untreated diffuse large B-cell lymphoma.

Investigators identified that early changes in standardized uptake value corrected for lean body mass may be able to predict pathologic complete response to pertuzumab AND trastuzumab in patients with HER2-positive breast cancer.

Patients with head and neck cancer who live in rural counties are 50% more likely to die from suicide compared with individuals residing in urban or metropolitan areas.

Trends towards missing key moments for end-of-life discussions when meeting with patients who have stage IV cancer can be overcome with existing strategies for successful EOL conversations.

Pembrolizumab met its primary end point of prolonged recurrence-free survival in the phase 3 KEYNOTE-716 trial for patients with stage II resected high-risk melanoma.

The cost of treating and managing breast cancer will rise two-and-a-half times by 2030 due to expected increases in young women being diagnosed with metastatic disease.

Oncologists can now use the International Esodata Study Group’s risk predictor model to identify patients with esophageal cancer who might be at a very high-risk of death following an esophagectomy.

Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.

Tumor size and grade appeared to be associated with long-term survival in patients with estrogen receptor–positive/ERBB2-negative breast cancer who have undergone treatment with tamoxifen.

Atezolizumab, which previously demonstrated positive results in the IMpower010 trial, was granted a priority review by the FDA for use in non–small cell lung cancer.

Three-year invasive disease-free survival was associated with the use of trastuzumab emtansine in patients with HER2-positive breast cancer.

Immunotherapy agent nemvaleukin alfa was granted an FDA fast track designation for the treatment of patient’s mucosal melanoma for previously undergone treatment with an anti-PD-L1 therapy.

The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.

Zanubrutinib yielded a high response rate and extended progression-free survival in patients with relapsed/refractory mantle cell lymphoma.

Although pembrolizumab added to chemoradiotherapy was well tolerated in patients with stage II/III locally advanced rectal cancer, the neoadjuvant rectal score vs FOLFOX/chemoradiotherapy suggest that further study into its utility in this setting may not be supported.

Patients with non–small cell lung cancer who were treated with durvalumab plus stereotactic body radiotherapy were found to have a major pathological response and was well tolerated among the population.